Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy: Considerations for scientists and funding agencies

• Published in: Virus research Vol. 248; pp. 53 - 62
• Main Authors: Bartenschlager, Ralf, Baumert, Thomas F., Bukh, Jens, Houghton, Michael, Lemon, Stanley M., Lindenbach, Brett D., Lohmann, Volker, Moradpour, Darius, Pietschmann, Thomas, Rice, Charles M., Thimme, Robert, Wakita, Takaji
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.03.2018
• Subjects: antiviral agents; cell biology; chronic hepatitis C; Direct acting antiviral therapy; genotype; HCV research funding; HCV vaccine; Hepatitis C virus; Human health and pathology; Immune reconstitution; Life Sciences; liver transplant; neoplasms; patients; research support; risk; scientists; sterilizing immunity; vaccines; viruses; Immune reconstitution; HCV vaccine; Direct acting antiviral therapy; HCV research funding

•New direct-acting antivirals (DAAs) eliminate persistent hepatitis C virus infection in >95% of patients.•DAAs are so successful, some question the need for continued research.•Critical public health, translational and clinical challenges remain.•A vaccine that prevents chronic infection is esse...